November Is a Crucial Month for this Coronavirus Vaccine Stock
Our experts issued a rare "Double Down" Buy alert on this one stock... Learn more.
Inovio Pharmaceuticals (NASDAQ: INO) made headlines in the spring as it became one of the leaders in the coronavirus vaccine race. The clinical-stage biotech designed its potential vaccine in three hours based on the genetic sequence of the coronavirus. And it became one of the first to launch a human trial of its potential vaccine -- only a month behind one of today's leaders, Moderna (NASDAQ: MRNA). As a result, Inovio shares soared 860% in the first half of the year.
But troubles have since shaken the coronavirus vaccine candidate program -- and the stock price. Investors were disappointed by a lack of detail in Inovio's initial trial data report, and more recently, the U.S. Food and Drug Administration halted the start of the company's late-stage study. The shares are now down 69% from their June peak.
Source Fool.com
